Loading stock data…
KNSA
$55.27+1.49 (+2.77%)
Market ClosedLast close May 1
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Kiniksa Pharmaceuticals International, plc in the Healthcare sector is trading at $55.27. The stock is currently near its 52-week high of $55.28, remaining 36.8% above its 200-day moving average. Technical signals show overbought RSI of 70 and bullish MACD crossover, explaining why KNSA maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 70) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$55.27
Potential Downside
68.3%
Whystock Fair Value$17.50
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokin...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.29B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
57.39
Beta
Defensive asset. Lower volatility than the S&P 500.
0.06
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
0.84%
Volume
Today's trading volume
854,206
Recent News
Kiniksa Pharmaceuticals International (KNSA) Is Up 29.2% After Raising 2026 Net Product Revenue Guidance
Kiniksa Pharmaceuticals International, plc reported past first-quarter 2026 results with revenue of US$214.27 million and net income of US$22.59 million, alongside basic earnings per share from continuing operations of US$0.30. The company also raised its 2026 net product revenue outlook to a range of US$930 million to US$945 million, signaling increased confidence in its ARCALYST franchise and broader portfolio execution. We’ll now examine how Kiniksa’s raised 2026 revenue guidance shapes...
Kiniksa Pharmaceuticals International (KNSA) Announces Q1 2026 Financial Results
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) is one of the best drug stocks to buy according to analysts. Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced its fiscal Q1 2026 financial results on April 28 and also provided updates regarding its recent portfolio execution. The company reported that net product revenue for ARCALYST® in fiscal Q1 2026 reached […]
Kiniksa Pharmaceuticals International PLC (KNSA) Q1 2026 Earnings Call Highlights: Robust ...
Kiniksa Pharmaceuticals International PLC (KNSA) reports a 56% increase in ARCALYST revenue and raises full-year guidance, while advancing clinical trials and launching innovative marketing campaigns.
Kiniksa Pharmaceuticals International Q1 Earnings Call Highlights
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) reported first-quarter 2026 results and provided updates on commercial execution for ARCALYST and progress across its clinical pipeline, including KPL-387 and KPL-1161. Management highlighted continued growth in ARCALYST prescribing and raised full
Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue Estimates
Kiniksa Pharmaceuticals International, plc (KNSA) delivered earnings and revenue surprises of +50.00% and +5.24%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?